NEWS RELEASE

New Data on Hologic's AI-Powered Mammography Technology to Be Presented at EUSOBI

2025-09-26

Research suggests AI may help identify more aggressive breast cancers and perform comparably to experts in breast cancer screening

MARLBOROUGH, Mass.--(BUSINESS WIRE)-- Data from two groundbreaking studies evaluating the performance of Hologic's (Nasdaq: HOLX) artificial intelligence (AI)-powered mammography technology will be presented today at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting in Aberdeen, Scotland.

New Data on Hologic's AI-Powered Mammography Technology to Be Presented at EUSOBI

"These results underscore AI's ability to make breast cancer screening more accurate and efficient, and its potential to provide valuable insights about each patient's unique tumor biology," said Mark Horvath, President, Breast and Skeletal Health Solutions at Hologic. "We're proud to work with top researchers around the world to continue to advance this technology and improve care for women everywhere."

The first study, conducted at Massachusetts General Hospital in the U.S., aimed to evaluate whether AI scores on 3D mammography (digital breast tomosynthesis) screening exams are associated with tumor characteristics, including histologic grade and lymph node status. Researchers retrospectively analyzed approximately 600 exams performed between 2016 and 2019 using Hologic's Genius AI® Detection 2.0 mammography solution. All cases were biopsy-proven cancers; 80% were invasive and 20% were ductal carcinoma in situ (DCIS).

To indicate the likelihood that breast cancer is present, the Genius AI Detection technology assigns a score to each suspicious lesion on an exam and then takes all the scores together to create an overall "case score." A score between 51% and 75% corresponds to a 1 in 61 likelihood of cancer, while a case score between 76% and 100%

corresponds to a 1 in 27 likelihood. In the study, AI case scores were higher for higher-grade tumors and node-positive cancers — features associated with more aggressive disease.

“AI is quickly becoming a valuable second set of eyes for radiologists, helping to flag cancers sooner, and our study suggests an added benefit of identifying those that are more likely to be aggressive,” said Dr. Manisha Bahl, M.D., MPH, FSBI, Associate Medical Director of Quality at Mass General Brigham and Associate Professor of Radiology at Harvard Medical School, who will be presenting the results at EUSOBI. “These findings are noteworthy because, for patients with more aggressive cancers, earlier detection allows treatment to begin sooner, which can improve clinical outcomes.”

The second study, presented by Professor Yan Chen, Ph.D., Chair of Digital Screening and Head of the Digital Cancer Screening Research Group at the University of Nottingham, UK, tested how well Hologic’s Genius AI Detection solution performed compared with radiologists. In this study, 108 radiologists from the UK and U.S. reviewed 75 clinically challenging breast cancer cases. The AI system also read the same cases.

The AI technology demonstrated similar performance to radiologists in finding cancers, with higher sensitivity but lower specificity. While the study is ongoing, these early results suggest AI could be a useful tool in helping radiologists diagnose breast cancer early. In many countries, each mammogram is checked by two radiologists and workforce shortages can make this difficult. These findings show AI’s potential to help fill this gap.

In addition to its AI-powered technologies, Hologic is showcasing its latest breast surgery innovations at EUSOBI, including the next-generation Sentimag® Gen 3 device for tumor localization and breast cancer staging. The product was developed by UK-based acquisition Endomag and was launched in Europe earlier this year.

Hologic will host multiple education sessions and workshops throughout the congress.

About Genius AI Detection Solution

Hologic’s Genius AI Detection solution is an innovative mammography screening technology designed to locate lesions likely representing breast cancer. Suspicious areas are highlighted at radiologists’ workstations for concurrent reading to support smart, decisive interpretation. Hologic's deep learning algorithm is fed by the accumulation of a large, diverse patient base, providing rich insight and intelligence. For more information please visit **Genius AI™ Detection Technology | Hologic**.

About Hologic, Inc.

Hologic, Inc. (Nasdaq: HOLX) is a global leader in women’s health dedicated to developing innovative medical

technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit **www.hologic.com** and connect with us on **LinkedIn**, **Facebook**, **X, Instagram** and **YouTube**.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to **womenshealth@hologic.com**.

SOURCE: Hologic, Inc.

Media Contact:

Bridget Perry
Senior Director, Corporate Communications
(+1) 508.263.8654
bridget.perry@hologic.com

Investor Contact:

Michael Watts
Corporate Vice President, Investor Relations
(+1) 858.410.8514
michael.watts@hologic.com

Source: Hologic, Inc.